Pharmacyclics LLC.
114
3
14
80
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
16.7%
19 terminated/withdrawn out of 114 trials
80.8%
-5.7% vs industry average
19%
22 trials in Phase 3/4
75%
60 of 80 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (114)
A Study to Customize Ibrutinib Treatment Regimens for Participants With Previously Untreated Chronic Lymphocytic Leukemia
Role: collaborator
A Study of the Combination of Ibrutinib Plus Venetoclax Versus Chlorambucil Plus Obinutuzumab for the First-line Treatment of Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
Role: collaborator
A Long-term Extension Study of PCI-32765 (Ibrutinib)
Role: collaborator
Obinutuzumab, Ibrutinib, and Venetoclax for the Treatment of Previously Untreated Stage II-IV Follicular Lymphoma
Role: collaborator
Rituxan/Bendamustine/PCI-32765 in Relapsed DLBCL, MCL, or Indolent Non-Hodgkin's Lymphoma
Role: collaborator
Study of Ibrutinib and Rituximab in Treatment Naïve Follicular Lymphoma
Role: lead
Ibrutinib and Lenalidomide in Treating Patients With Myelodysplastic Syndrome
Role: collaborator
Obinutuzumab and Ibrutinib as Front Line Therapy in Treating Patients With Indolent Non-Hodgkin's Lymphomas
Role: collaborator
Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Patients With Newly Diagnosed or Refractory/Recurrent Primary Central Nervous System Lymphoma (PCNSL) and Refractory/Recurrent Secondary Central Nervous System Lymphoma (SCNSL)
Role: collaborator
Ibrutinib With Rituximab and Lenalidomide for Patients With Recurrent/Refractory Primary or Secondary Central Nervous System Lymphoma (PCNSL/SCNSL)
Role: collaborator
Ibrutinib as an Immune Modulating Agent for Patients With Asymptomatic, High-risk CLL/SLL Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Role: collaborator
Study of Ibrutinib in Combination With Revlimid/Dexamethasone in Relapsed/Refractory Multiple Myeloma
Role: collaborator
A Phase II Study of Ibrutinib Plus FCR in Previously Untreated, Younger Patients With Chronic Lymphocytic Leukemia
Role: collaborator
Phase 1/2 Dose Finding and Safety Study of Ibrutinib in Pediatric Subjects With Chronic Graft Versus Host Disease (cGVHD)
Role: lead
A Study of Ibrutinib With Rituximab in Relapsed or Refractory Mantle Cell Lymphoma
Role: collaborator
Ibrutinib in Combination With GA101 (Obinutuzumab) in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Patients.
Role: collaborator
Ibrutinib as Early Therapy in Chronic Lymphocytic Leukemia (CLL)
Role: collaborator
Ibrutinib + Venetoclax in Untreated WM
Role: collaborator
PCI-24781 in Combination With Doxorubicin to Treat Sarcoma
Role: collaborator
A Study of Ibrutinib With Rituximab in People With Untreated Marginal Zone Lymphoma
Role: collaborator